Document Detail

Thrombocytopenia associated with antithrombotic therapy in patients with cardiovascular diseases: diagnosis and treatment.
MedLine Citation:
PMID:  18828644     Owner:  NLM     Status:  MEDLINE    
Agents with antiplatelet and anticoagulant activity have been proved to be effective in reducing the incidence of complications following acute coronary syndrome, percutaneous coronary intervention, and cardiopulmonary bypass. However, these agents, including heparin, glycoprotein IIb/IIIa receptor inhibitors, and thienopyridines, are associated with increased risk of bleeding and thrombocytopenia and have been administered together with increasing frequency in a variety of cardiovascular settings. Therefore, clinicians must be familiar with the safety and rational use of these potent antithrombotic agents. Clinical features of thrombocytopenia range from bleeding to thrombosis, even death, and therapy is very different depending on the underlying cause. Additionally, patients may sometimes need urgent intervention or surgery. Thus, it is essential to quickly discriminate the etiology and start appropriate therapy. This review highlights the pathogenesis, clinical and laboratory manifestation, differential diagnosis, and treatment of antithrombotic drug-induced thrombocytopenia in cardiovascular diseases.
Burcak Kilickiran Avci; Ali Oto; Osman Ozcebe
Related Documents :
17067704 - Myocardial infarction complicating the initial phase of an ovarian stimulation protocol.
15973924 - Heparin-induced thrombocytopenia and the use of r-hirudin during cardiopulmonary bypass.
9250564 - Ticlopidine-induced elevated liver enzymes.
18852594 - Drug-eluting stents in a patient with favism: is the aspirin administration safe?
22297544 - Stress cardiomyopathy: a syndrome of catecholamine-mediated myocardial stunning?
3315574 - Summary of early clinical experience with anisoylated plasminogen streptokinase activat...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of cardiovascular drugs : drugs, devices, and other interventions     Volume:  8     ISSN:  1175-3277     ISO Abbreviation:  Am J Cardiovasc Drugs     Publication Date:  2008  
Date Detail:
Created Date:  2008-10-02     Completed Date:  2009-01-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100967755     Medline TA:  Am J Cardiovasc Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  327-39     Citation Subset:  IM    
Department of Cardiology, Faculty of Medicine, Baskent University, Istanbul, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiovascular Diseases / drug therapy*
Diagnosis, Differential
Drug Monitoring
Fibrinolytic Agents / adverse effects*,  therapeutic use
Heparin / adverse effects,  therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
Pyridines / adverse effects,  therapeutic use
Thrombocytopenia / chemically induced*,  diagnosis,  therapy
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Pyridines; 0/thienopyridine; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Therapeutic potential of adult progenitor cells in the management of chronic myocardial ischemia.
Next Document:  Intravenous conivaptan.